Research Article
Inhibition of the SARS-CoV-2 Main Protease by Isoquercitrin γ-Cyclodextrin Inclusion Complex Formulations: A Biochemical and In Silico Study
Table 2
Inhibition of Zika virus NS2B-NS3 protease by selected compounds.
| | Formulation (active compound) | Control (uninhibited reaction) | Positive control (tannic acid) | SunActive DCD™ (diosmetin-7-O-glucoside) | SunActive HCD™ (hesperetin-7-O-glucoside) | SunActive NCD™ (naringenin-7-O-glucoside) | SunActive QCD™ (quercetin-3-O-glucoside) |
| | V0 | 4.02 | 0.006 | 0.87 | 3.77 | 3.34 | 0.99 | | Inhibition | −/− | Active | Active | Not active | Not active | Active | | IC50 | −/− | 0.020 μM ± 0.003 μM | 98.1 μM ± 4.3 μM | −/− | −/− | 97.8 μM ± 4.0 μM |
|
|
Assays were performed using 20 μM substrate, 500 μM active compounds, and 5 nM enzyme.
|
